Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults.

When adults and older children catch RSV, they usually have milder symptoms that are similar to those of a cold. But RSV can be serious for some, including: People over 65 Those with a weakened ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published online April 1 in JAMA Network Open.

The Ministry of Public Health (MoPH) has advised the public, especially the vulnerable to take the Respiratory Syncytial Virus (RSV) ...

Just 1 in 10 older adults who participated in the study had received an RSV vaccine during the first season when RSV vaccines were available, from 2023 to 2024, the data showed.

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

(NASDAQ:MRNA), currently trading near its 52-week low of $29.25 and down over 70% in the past year, announced today that the Australian Therapeutic Goods Administration (TGA) has approved its ...

RSV poses a significant health risk, especially to older adults. During the 2024 Australian winter, RSV cases in adults aged 65 and older were close to two-thirds the number of influenza cases in ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active ... a common respiratory virus with symptoms that can be severe or even ...

Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...